Visit COVID-19 resources

[Skip to Content]


Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Monitoring

Updated Guidelines December 2020 Following the publication of the RCOphth recommendations for monitoring in hydroxychloroquine and chloroquine users in 2018, new published evidence prompted a review of the guideline. Recent data have highlighted that hydroxychloroquine retinopathy is more common than previously reported. The prevalence in long-term users appears to be around 7.5% and depending on

RCOphth guideline: Hydroxychloroquine and Chloroquine Retinopathy: NEW screening recommendations February 2018

The new guideline on screening for hydroxychloroquine and chloroquine retinopathy is written in response to evidence from the United States that shows that hydroxychloroquine retinopathy is more common than previously recognised. Implementation of the guideline’s recommendations will prevent iatrogenic visual loss. The new guideline also makes recommendations regarding the techniques and timing of baseline and

Clinical Guidelines

Our guidelines are systematically generated to help clinicians make better decisions about appropriate healthcare for specific eye disorders, enhancing clinician and patient decision making by describing and appraising the scientific evidence and reasoning behind clinical recommendations. They are developed to make recommendations for the majority of clinical situations; however they are intended as an aid